$OMER - "It is harder to estimate potential market size for IgA Nephropathy given that there are approximately 300,000 people between the United States and Europe, not including Asia which has a higher incidence rate. Given that there is no currently approved treatment, there would be ample room for Nasoplimab to be used in a significant portion of patients. If we assume that only 10% of patients will use Narsoplimab, that leads to approximately 30,000 individuals between the United States and Europe. If we take the same pricing from HSCT-TMA, $250,000, that would yield a potential market of $7.5 billion. Keep in mind that that number does not include the market potential in Asia, and estimates could be significantly higher as the company comes closer to filing for approval."